Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib, Sintilimab, and SBRT in Gastric/GEJ Adenocarcinoma
NCT06977061Phase 3Not yet recruiting
- Start
- Jun 2025
- Primary completion
- Jun 2026
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
01
Overview
A Phase 3 trial of fruquintinib, sintilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
fruquintinibsintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06977061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06977061.